Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Others

Ratios

Kodiak Sciences (KOD) Asset Writedowns and Impairment (2025)

Kodiak Sciences filings provide 1 years of Asset Writedowns and Impairment readings, the most recent being $1.9 million for Q1 2025.

Quarterly Asset Writedowns and Impairment changed N/A to $1.9 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $1.9 million through Dec 2025, changed N/A year-over-year, with the annual reading at $1.9 million for FY2025, N/A changed from the prior year.
Asset Writedowns and Impairment hit $1.9 million in Q1 2025 for Kodiak Sciences.
Across five years, Asset Writedowns and Impairment topped out at $1.9 million in Q1 2025 and bottomed at $1.9 million in Q1 2025.